Id: acc3273
Group: 2sens
Protein: Tau
Gene Symbol: MAPT
Protein Id: P10636
Protein Name: TAU_HUMAN
PTM: acetylation
Site: Lys174
Site Sequence: EATRQPSGTGPEDTEGGRHAP
Disease Category: Nervous system diseases
Disease: Alzheimer's Disease
Disease Subtype:
Disease Cellline: N2aSwe?
Disease Info:
Drug: Cilostazol + resveratrol
Drug Info: "Cilostazol is a medication used to treat intermittent claudication by improving blood flow. | Resveratrol is a natural compound with potential health benefits, including antioxidant and anti - inflammatory properties. "
Effect: modulate
Effect Info: "Cilostazol inhibits Aβ-induced tau acetylation. By activating the CK2α/SIRT1 pathway, it suppresses P300, activates SIRT1, and alleviates tauopathy."
Note:
Score: 4.0
Pubmed(PMID): 24254769
Sentence Index:
Sentence:

Sequence & Structure:

MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTPTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAEEAGIGDTPSLEDEAAGHVTQEPESGKVVQEGFLREPGPPGLSHQLMSGMPGAPLLPEGPREATRQPSGTGPEDTEGGRHAPELLKHQLLGDLHQEGPPLKGAGGKERPGSKEEVDEDRDVDESSPQDSPPSKASPAQDGRPPQTAAREATSIPGFPAEGAIPLPVDFLSKVSTEIPASEPDGPSVGRAKGQDAPLEFTFHVEITPNVQKEQAHSEEHLGRAAFPGAPGEGPEARGPSLGEDTKEADLPEPSEKQPAAAPRGKPVSRVPQLKARMVSKSKDGTGSDDKKAKTSTRSSAKTLKNRPCLSPKHPTPGSSDPLIQPSSPAVCPEPPSSPKYVSSVTSRTGSSGAKEMKLKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSRSRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
MAPT TILAVONEMAB Microtubule-associated protein tau inhibitor 2 Terminated Alzheimer disease ClinicalTrials
MAPT ZAGOTENEMAB Microtubule-associated protein tau inhibitor 2 Completed Alzheimer disease ClinicalTrials
MAPT SEMORINEMAB Microtubule-associated protein tau inhibitor 2 Completed Alzheimer disease ClinicalTrials
MAPT BEPRANEMAB Microtubule-associated protein tau inhibitor 2 Active, not recruiting Alzheimer disease ClinicalTrials
MAPT GOSURANEMAB Microtubule-associated protein tau inhibitor 2 Terminated Alzheimer disease ClinicalTrials
MAPT TILAVONEMAB Microtubule-associated protein tau inhibitor 2 Completed Alzheimer disease ClinicalTrials
MAPT SEMORINEMAB Microtubule-associated protein tau inhibitor 2 Terminated Alzheimer disease ClinicalTrials
MAPT TILAVONEMAB Microtubule-associated protein tau inhibitor 2 Terminated progressive supranuclear palsy ClinicalTrials
ClinicalTrials
MAPT GOSURANEMAB Microtubule-associated protein tau inhibitor 2 Terminated Classical progressive supranuclear palsy ClinicalTrials
MAPT SEMORINEMAB Microtubule-associated protein tau inhibitor 1 Completed Alzheimer disease ClinicalTrials
MAPT POSDINEMAB Microtubule-associated protein tau inhibitor 1 Completed Alzheimer disease ClinicalTrials
MAPT ZAGOTENEMAB Microtubule-associated protein tau inhibitor 1 Completed Alzheimer disease ClinicalTrials
ClinicalTrials
MAPT GOSURANEMAB Microtubule-associated protein tau inhibitor 1 Completed progressive supranuclear palsy ClinicalTrials
MAPT TILAVONEMAB Microtubule-associated protein tau inhibitor 1 Completed progressive supranuclear palsy ClinicalTrials
MAPT BEPRANEMAB Microtubule-associated protein tau inhibitor 1 Active, not recruiting progressive supranuclear palsy ClinicalTrials
MAPT BEPRANEMAB Microtubule-associated protein tau inhibitor 1 Completed progressive supranuclear palsy ClinicalTrials
MAPT GOSURANEMAB Microtubule-associated protein tau inhibitor 1 Terminated Classical progressive supranuclear palsy ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
MAPT-Lys24
Cancer Intensity
BRCA -0.707
COAD
HGSC
ccRCC
GBM 0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
K 174 D Alzheimer's disease Acetylation 33910019
K 174 P Tauopathies Acetylation 35269542
K 174 P Alzheimer's disease Methylation 22033876
K 174 U Alzheimer's disease Acetylation 26390242

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: